|
Volumn 48, Issue 11, 2013, Pages 1395-1400
|
Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: A study by the European group for blood and marrow transplantation
a a b c d e f g h i j k l m n o p q r s |
Author keywords
[No Author keywords available]
|
Indexed keywords
BUSULFAN;
CYCLOPHOSPHAMIDE;
FLUDARABINE;
MELPHALAN;
ADULT;
AGED;
ALLOGENEIC STEM CELL TRANSPLANTATION;
ARTICLE;
AUTOLOGOUS STEM CELL TRANSPLANTATION;
CANCER GROWTH;
CANCER PROGNOSIS;
CANCER RECURRENCE;
CYTOMEGALOVIRUS INFECTION;
DONOR SELECTION;
ENGRAFTMENT;
FEMALE;
GRAFT VERSUS HOST REACTION;
HUMAN;
LIVING DONOR;
MAJOR CLINICAL STUDY;
MALE;
MORTALITY;
MULTIPLE MYELOMA;
NONRELAPSE MORTALITY;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
REDUCED INTENSITY CONDITIONING;
WHOLE BODY RADIATION;
ADULT;
AGED;
FEMALE;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HUMANS;
MALE;
MIDDLE AGED;
MULTIPLE MYELOMA;
PROGNOSIS;
RECURRENCE;
TREATMENT OUTCOME;
YOUNG ADULT;
|
EID: 84887242920
PISSN: 02683369
EISSN: 14765365
Source Type: Journal
DOI: 10.1038/bmt.2013.73 Document Type: Article |
Times cited : (37)
|
References (0)
|